32 results about "Teprenone" patented technology

Topical use of teprenone in a cosmetic or dermopharmaceutical composition as an active preventing and/or limiting the skin cells sénescence and/or protecting the general state of the skin.

The invention discloses application of geranylgeranylacetone to the preparation of a medicament for preventing and/or treating opiates drug addiction, relating to the technical field of medicines. Geranylgeranylacetone is taken as a medicament for preventing and treating the opiates drug addiction or is used for preparing a medicament for preventing and treating the opiates drug addiction. One or more medicinally acceptable conventional medicinal auxiliary materials can also be added into geranylgeranylacetone to prepare capsules, pills, powder, tablets, granules, oral liquids, injections and the like. Geranylgeranylacetone has the effects of antagonizing conditioned place preference behaviors caused by morphine and increase in autonomic activities induced by morphine and relieving the function of abstinence symptom action, is used for preventing and treating the opiates drug addiction, and has the advantages of remarkable curative effect, high safety, addiction resistance, low price, capability of lowering the economic burden of a patient, and the like.

This invention relates to synthetic method of a ( E, E) - geranyl linalool. The invention takes (E) - nerolidol as raw material. The hydroxyl is shield by dihydropyrane, gain ( E) - nerolidol tetrahydropyrane aether; selenium dioxide and teri-butyl hydroperoxide selectively oxidize the anti-form methyl of ( E) - nerolidol tetrahydropyrane aether to gain anti-form allyl position hydroxylated oxidative product ( E, E) - 12 - hydroxy nerolidol tetrahydropyrane aether, transit halogenating reaction to gain ( E, E) - 12 - halogeno- nerolidol tetrahydropyrane aether, then take reaction with isopropyl methyl ketone that is selectively divested one proton by diisopropyl amido lithium, generate ( 6E, 10E) - 2, 6, 10, 14 - tetramethyl - 14 - ( tetrahydropyrane - 2 - oxygen) -16 - 6, 10, 15 - triene - 3 - ketone, use sodium borohydride to reduce to gain ( 6E, 10E) - 2, 6, 10, 14 - tetramethyl - 14 - ( tetrahydropyrane - 2 - oxygen) -16 - 6, 10, 15 - triene - 3 - alcohol, takes reaction with sulfonyl chloride or sulphonic acid ester with alkali presence to gain ( 6E, 10E) - 2, 6, 10, 14 - tetramethyl - 14 - ( tetrahydropyrane - 2 oxygen) -16 - 6, 10, 15 - triene - 3 - alcoholic sulphonic acid ester, then divide sulphonic acid ester group under base catalysis to gain ( E, E) - geranyl linalool tetrahydropyrane aether, and by deprotection to gain ( E, E) - geranyl linalool. ˕For the configuration of ( E) - nerolidol 3 position tertiary carbon is not influenced in the course of reaction, if use ( E) - nerolidol that has optical activity as raw material, should gain optical active ( E, E) - geranyl linalool. ((E, E)-geranyl linalool can replace Teprenone and such type medicament intermediate, natural product intermediate, insect pheromone and spice etc.

The invention relates to a method for separating all trans-teprenone under low temperature. The method comprises the following specific steps: an ether-type organic solvent is added in low-chain liquid alkane, and full and uniform stirring is performed, such that a diluting agent is prepared; the prepared diluting agent is added into a jacketed container; a teprenone isomer mixture is added; stirring is started; circulating hot water is introduced into the jacket; stirring is carried out for uniformly mixing the materials; the circulating hot water in the container jacket is discharged, and a refrigerant is introduced; crystallization is carried out under stirring, such that teprenone crystals are obtained; the teprenone crystals are placed in a vacuum suction filtration device, and vacuum suction filtration is carried out; an upper-layer filter cake is taken out and is dissolved under normal temperature, such that all trans-teprenone is obtained. The method assists in fundamentally solving an all trans-teprenone separation problem. The separation temperature is controllable. The all trans-teprenone obtained after separation has the advantages of high content and low impurity content. During the process, solvent amount is low; the solvent can be recycled and applied mechanically; and no three-waste is generated. The method is suitable for large-scale production.

An oral disintegrating tablet of teprenone contains teprenone, filler chosen from MCC, dextrin, lactose and mannitol, disintegrant chosen from L-HPC, PPVP, CMS-Na and their mixture, flavouring chosen from nature or artificial sweetening agent, antioxidant chosen from VC, VE and BHA, lubricant chosen from magnesium stearate, magnesium lauryl sulfate and talc powder, and flowing aid chosen from superfine silicon gel powder and talc powder. Its preparing process is also disclosed.

The invention discloses a preparation method for an intermediate (5E, 9E)-farnesyl acetone of teprenone. The preparation method comprises the following steps: (1) carrying out reaction on (2E, 6E)-farnesol together with methanesulfonyl chloride and lithium chloride to obtain (2E, 6E)-farnesyl chloride; (2) carrying out reaction (2E, 6E)-farnesyl chloride together with ethyl acetoacetate and sodium ethoxide to generate (5E, 9E)-ethoxycarbonyl ethyl farnesyl acetone; and (3) decarboxylating (5E, 9E)-ethoxycarbonyl ethyl farnesyl acetone in the alkaline solution of potassium hydroxide by saponifying to obtain the (5E, 9E)-farnesyl acetone. The innovative synthesis process is used for preparing the (5E, 9E)-farnesyl acetone, the toxicity of adopted raw materials and by-products are low, and the raw materials and the by-products are easy to treat. In addition, materials react under mild reaction conditions, the preparation method is easy to operate, the yield and the purity of the (5E, 9E)-farnesyl acetone are high, and the content of isomers in (5E, 9E)-farnesyl acetone is low.

The invention relates to synthesis methods of teprenone and an intermediate thereof. The synthesis of the intermediate all-trans (5E,9E)-farnesyl acetone comprises: 1) in the presence of a catalyst, carrying out a carroll rearrangement reaction on the mixture of 5E-nerolidol and 5Z-nerolidol and hydrocarbonyl acetoacetate to obtain the isomer mixture of (5Z,9Z)-farnesyl acetone, (5Z,9E)-farnesyl acetone, (5E,9Z)-farnesyl acetone, and (5E,9E)-farnesyl acetone, wherein the content of (5E,9E)-farnesyl acetone in the isomer mixture is controlled at more than 18%; and 2) carrying out low-temperature crystallization separation on the isomer mixture in a moderately polar solvent to obtain the all-trans (5E,9E)-farnesyl acetone. According to the present invention, the high-purity all-trans (5E,9E)-farnesyl acetone is obtained by using the mixture of 5E-nerolidol and 5Z-nerolidol as the raw material through the low-temperature crystallization separation, such that the teprenone with the qualified quality can be conveniently obtained.

The invention discloses new application of teprenone, namely application to preparing a medicine for preventing and/or treating weight reduction caused by opioid drug habituation and abstinence relapsing, and relates to the technical field of medicines. The teprenone can resist mice weight reduction caused by morphine habituation and abstinence; in addition, in terms of the molecular level, GGA obviously restrains NAc area NR2B expression rise induced by morphine relapsing lighting; and the teprenone can be used for preventing and treating weight reduction caused by opioid drug habituation and abstinence relapsing.

The invention discloses a novel application of teprenone, and particularly relates to an application in preparing a drug for preventing and/or treating readdiction in opiates narcotics, and relates to the technical field of medicine. The experiment result shows that after the teprenone is orally taken for 7 days, the conditioned place preference test is carried out on re-addiction mouse after the morphine addiction disappears; when GGA is previously orally taken, the mouse conditioned place preference caused by the readdiction in the morphine can be remarkably inhibited; the expression of NAc-zone NR2B induced by readdiction of morphine can be remarkably inhibited on the molecular level, and the teprenone can be used for preparing the drug for preventing and/or treating opiates narcotics.

The invention relates to a new application of teprenone in preparation of a medicament for preventing and treating morphine-induced liver injury, and discloses teprenone capable of protecting liver cells from being poisoned by morphine, inhibiting morphine-induced cell apoptosis and weakening morphine-induced lipid per-oxidative injury. The teprenone can be used for preventing and treating the morphine-induced liver injury.

The invention discloses an application of teprenone in the preparation of drugs for preventing and/or treating neurotoxicity caused by methamphetamine, belonging to the technical field of medicines. The teprenone has the effect of resisting neurotoxicity caused by methamphetamine. A test result shows that the teprenone has the capabilities of protecting rat pheochromocytoma cells, namely PC12 cells to be free from cell apoptosis caused by methamphetamine and recovering the pro-caspase3 protein reduction caused by methamphetamine, and has the advantages of obvious treatment effect, high safety, low cost and suitability for practical popularization and application.

The present invention relates to an application of teprenone (geranylgeranylacetone, GGA) for resisting heat apoplexy. Under the condition of peroral administration the teprenone can obviously delay heat apoplexy incidence of rat in heat environment and can prolong surviving time of the rate with heat apoplexy.

The invention discloses a process for synthesizing teprenone.According to the process for synthesizing teprenone, nerolidol is adopted as an initial raw material and subjected to selenium dioxide and tert-butyl hydroperoxide oxidizing in sequence, nerolidol and dihydropyran are subjected to acid catalysis to form acetal, acetal reacts with a Grignard reagent on the presence of copper salt and reacts with methyl acetoacetate on the presence of aluminum salt, and the teprenone product consistent with the configuration of products sold on the market is obtained through four steps of reactions.According to a preparation method of teprenone, the raw material is cheap and easy to obtain, operation is easy and convenient, the reaction conditions are mild, and industrial production is expected to be achieved.

The invention provides a synthetic method of all-trans-teprenone. According to the method, specific raw materials are selected and combined with a proper catalyst, firstly geranyl geranyl bromide is prepared, and then the geranyl geranyl bromide reacts with acetone and lithium diisopropylamide in the presence of cuprous iodide to synthesize all-trans-teprenone. The method is high in process yield and high in purity, and a new thought is provided for synthesis of all-trans-teprenone.

The invention discloses teprenone (the other name is pentatetraterpenone, and the chemical name is 6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraterpene-2-one). The invention also relates to application of the compound in preparation of medicines for preventing and treating fatty liver/steatohepatitis. In addition to being prepared into capsules, the compound can also be prepared into tablets, powder, granules, oral liquid, injection and other medicine forms. In-vitro test results show that after FL83b cells of an in-vitro fatty degeneration model are stimulated by GGA for 24 hours, lipid droplets in the cells are obviously reduced; and animal experiment results are as follows: 12 weeks after continuous administration of 200mg/kg of GGA to a mouse with fatty liver induced by high fat-cholesterol-fructose diet, the weight gain of the mouse with high fat diet is reduced; meanwhile, the level of serum alanine aminotransferase is remarkably reduced, and the level of cholesterol is remarkably reduced; in addition, inflammation in liver tissues is remarkably relieved, and the fatty degeneration area is remarkably reduced; the serum insulin level is obviously reduced, and the insulin resistance is obviously improved. The medicine is remarkable in curative effect, high in safety, low in price and capable of relieving the economic burden of patients.

The invention relates to an application of teprenone and derivatives (structure I) thereof in the prevention and treatment of viral hepatitis, in particular for the prevention and treatment of hepatitis B and hepatitis C. The experimental results show that the antiviral activity of all-trans teprenone (5E-GGA) is significantly higher than that of monocis-preprepone (5Z-GGA), and is also higher than that of the mixture of the two preprepone isomers.

The invention relates to all-trans-teprenone and mono-cis-teprenone and application of a derivative (described as a formula I) of the all-trans-teprenone and mono-cis-teprenone in preparing a drug fortreating drug addiction and preventing drug addiction recurrence. The effects of the all-trans-teprenone (5E-GGA) is superior to the mono-cis-teprenone (5Z-GGA) and also a mixture of an all-trans-teprenone isomer and a mono-cis-teprenone isomer. In a mixture of cis-teprenone and trans-teprenone, the greater the weight ratio of the all-trans-teprenone is, the better the curative effect is.